To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you specific and relevant content

Title

This website is for healthcare professionals only

Welcome to BP Sanofi Campus

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus® (nirsevimab-alip), call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

This site is intended for healthcare professionals only and contains information on Sanofi medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs.

Welcome to Sanofi Campus

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

You are entering to Sanofi Content Site

You are about to leave the T1D website

Welcome to the T1D Step Ahead Sanofi website

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

References

asthma

Asthma

<h3 style="text-align:center;">Mucus Overproduction and Decreased Mucociliary Clearance Can Lead to Mucus Plugs1</h3>

<h3 style="text-align:center;">Mucus Plugs Can Be Identified and Quantified Using CT Imaging of the Lungs2</h3>

<h4 style="text-align:center;">Segments of each lobe are examined for mucus plugs and given a score of 1 (present) or 0 (absent). Segment scores of each lobe are summed to generate a total mucus score ranging from 0-20.</h4>

<figure class="table" style="width:100%;">
 <table>
 <tbody>
 <tr>
 <td style="background-color:#1C8EA1;">
 <h4 style="text-align:center;">High mucus scores (≥4 bronchial subsegments with 1 or more airways completely occluded with mucus) were associated with low FEV1 and air trapping in patients with chronic, severe asthma2</h4></td>
 </tr>
 </tbody>
 </table>
</figure>

Republished with permission of American Society for Clinical Investigation, from Journal of Clinical Investigation, Dunican EM, Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction, Vol 128/No. 3, Copyright 2018; permission conveyed through Copyright Clearance Center, Inc. CT, computed tomography; FEV1, forced expiratory volume in 1 second; IL, interleukin. 1. Jesenak M, et al. Respir Med. 2023;218:107372. 2. Dunican EM, et al. J Clin Invest. 2018;128(3):997-1009. 3. Tang M, et al. Am J Respir Crit Care Med. 2022;205(9):1036-1045. 4. Chan R, et al. J Allergy Clin Immunol Pract. 2023;11(1):195-199.e2.

<figure class="table" style="width:100%;">
 <table>
 <tbody>
 <tr>
 <td style="background-color:#1c8ea1;">
 <h3 style="text-align:center;">Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction</h3></td>
 </tr>
 </tbody>
 </table>
</figure>

<h3 style="text-align:center;">The SARP-3 Study Showed Persistence of Mucus Plugs in Asthma Patients Over 3 Years3</h3>

<figure class="table" style="width:100%;">
 <table>
 <tbody>
 <tr>
 <td style="background-color:#1c8ea1;">Low Global Mucus Score: 0.5-3.5</td>
 <td style="background-color:#E94C1F;">
 High Global Mucus Score: 4-202</td>
 </tr>
 </tbody>
 </table>
</figure>

<h3 style="text-align:center;">Persistent mucus plugs are associated with chronic OCS use and a greater symptom burden, measured by ACT33</h3>

<h2 style="text-align:center;">Presence of Mucus Plugs Is Associated With Worsening Clinical Asthma Outcomes</h2>

Republished with permission of American Society for Clinical Investigation, from Journal of Clinical Investigation, Dunican EM, Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction, Vol 128/No. 3, Copyright 2018; permission conveyed through Copyright Clearance Center, Inc. Reprinted from the American Journal of Respiratory and Critical Care Medicine, Tang M, et al, Mucus Plugs Persist in Asthma, and Changes in Mucus Plugs Associate with Changes in Airflow over Time, Vol 205/Issue 9, Copyright 2022, with permission from the American Thoracic Society. *Data from 146 of the 658 adult patients with asthma enrolled in SARP. Of those included in SARP (n=658), 66% of patients met American Thoracic Society/European Respiratory Society criteria for severe asthma. Patients were non-smokers and were required to have evidence of bronchial hyperresponsiveness or reversible airflow obstruction. ACT, Asthma Control Test; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; OCS, oral corticosteroid; SARP, Severe Asthma Research Program. 1. Jesenak M, et al. Respir Med. 2023;218:107372. 2. Dunican EM, et al. J Clin Invest. 2018;128(3):997-1009. 3. Tang M, et al. Am J Respir Crit Care Med. 2022;205(9):1036-1045. 4. Chan R, et al. J Allergy Clin Immunol Pract. 2023;11(1):195-199.e2.

ASTHMA

RESPIRATORY

Mucus Plugging Is a Key Component of Remodeling
in Asthma, Leading to Fixed Airway Obstruction

*All characteristics are mean unless otherwise noted. bAs the primary imaging endpoint did not reach statistical significance (P&gt;0.05), all subsequent endpoints were reported using nominal p-values. cThe statistical significance represents the correlations between 2 parameters. ACQ, asthma control questionnaire; BD, bronchodilator; CT, computed tomography; EOS, eosinophils; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; FOT, forced oscillation technique FRI, functional residual imaging; ICS, inhaled corticosteroids; ITT, intention-to-treat; iV/Q, image-based ventilation-perfusion ratio; LS, least squares; ppFEV1, percent predicted forced expiratory volume in 1 second; q2w, every 2 weeks.

<h3>Disclaimer: This study is not added yet in to the local label in Kingdom of Saudi Arabia.</h3>

VESTIGE study

VESTIGE Trial Results: Dupilumab in Type 2 Asthma

This video presents results from the Phase 4 VESTIGE trial, demonstrating how dupilumab improves airway structure and function in severe type 2 asthma. Using breakthrough Functional Respiratory Imaging technology, the study reveals structural improvements that conventional lung function tests may not detect.

Asthma

Latest Articles

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction

VESTIGE study

VESTIGE Trial Results: Dupilumab in Type 2 Asthma